Biomarker and Surrogate Targets for Successful Therapy in Polycythemia Vera (PV)

Serge Verstovsek MD, Richard Silver MD, Rubin Mesa MD, and Susan J. Leclair, PhD, CLS (NCA) discuss the roles of biomarkers and target levels in PV management. Maintaining hematocrit (Hct) level at or below 45% is a therapeutic target to reduce the risk of thrombosis in patients PV. Other hematologic findings may influence treatment goals, including Hct target, for individual patients.